Close Menu
    What's Hot

    Global Equity Release/Reverse Mortgage Primary Market on Track To Hit $56bn by 2035

    18 June 2025

    Church Mission Society Pension Scheme Joins Consolidator Clara Pensions

    17 June 2025

    The McGregor Construction (Highlands) Limited Pension Plan Completes Bulk Purchase Annuity Buy-In With Just Group

    16 June 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024

      12 June 2025

      Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market

      12 June 2025

      Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets

      12 June 2025

      Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

      12 June 2025

      Q&A: Matthew Sheridan, Health Data Analytics

      12 June 2025
    • Commentary

      Life Expectancy in Breast Cancer

      12 June 2025

      The Healthy Wealthy Population of the Life Settlement Market

      12 June 2025

      UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

      14 May 2025

      The Power of Uncorrelated Diversification During Market Volatility

      14 May 2025

      Overseeing BPA Growth Safely

      14 May 2025
    • Events
    • Magazine
    • News

      Global Equity Release/Reverse Mortgage Primary Market on Track To Hit $56bn by 2035

      18 June 2025

      Church Mission Society Pension Scheme Joins Consolidator Clara Pensions

      17 June 2025

      The McGregor Construction (Highlands) Limited Pension Plan Completes Bulk Purchase Annuity Buy-In With Just Group

      16 June 2025

      The London Waste Limited Pension Scheme Completes Bulk Purchase Annuity Buy-In with Royal London

      2 June 2025

      Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

      28 May 2025
    Subscribe
    Life Risk News
    Home » Solving The Obesity Paradox, When Being Fat Is Good For You

    Solving The Obesity Paradox, When Being Fat Is Good For You

    Features 15 March 2024Aaron WoolnerBy Aaron Woolner
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    Obesity is a killer, but nobody dies directly from being overweight. Instead, excess pounds are linked to a higher risk of getting type II diabetes, developing fatty liver, and having a stroke, while research links obesity to up to 8% of all cancer cases. 

    Obesity is a factor in all of the four main non-Covid causes of deaths in the UK in 2022, while diabetes itself is a risk factor for heart disease, the leading cause of mortality worldwide.  

    The number of overweight people is so high globally that the World Health Organisation has dubbed it an, ‘obesity epidemic’.  

    “There’s over a billion obese people globally and we know without any debate that being overweight increases your risk of chronic diseases such as diabetes, heart disease, cancer, and musculoskeletal disease,” says Nicola Oliver, Director of Life and Health at longevity specialists Medical Intelligence. 

    Being overweight may be a proxy for a number of leading causes of mortality but Rahul Nawander, Ontario-based Medical Director at life, health, and life settlement firm Fasano Associates, says that thinking over the dangers posed by obesity has changed over the last ten to 15 years. 

    Evidence has emerged that certain cohorts may in fact benefit from a certain amount of extra weight.  

    The Body Mass Index (BMI) has been the main indicator of the extent of someone’s obesity (or not). It is calculated by dividing a person’s body mass by the square of their height; a BMI over 25 means a person is considered overweight, more than 30 and they are considered obese.  

    Oliver says there is a fundamental problem with the use of BMI and that its relatively blunt approach can classify otherwise healthy people as obese.  

    “BMI may not be the best measure of obesity. Take the example of a professional rugby player or a bodybuilder, these people are by definition very fit but because of their muscle bulk they would be classified as overweight or possibly even obese. However, BMI remains a good proxy for measuring bodyweight” she says. 

    But Nawander says questions are also being raised over whether a high BMI is always negative for health. He says that, while traditionally, obesity has been considered as being bad and that people should look to lose weight if they were classified as obese, research has emerged which challenges this thinking – for some cohorts, at least.  

    “Several studies have found obesity is an independent predictor of mortality. Interestingly this research also found that when you look at people older than 65 there is a term known as the ‘obesity paradox’.  

    “What this means is that people in this age group who are obese tend to have a slightly better life expectancy compared to people who have a BMI of around 25 or even less. The hypothesis is that frailty becomes an issue after the age of 65 and a certain amount of extra weight can be helpful,” says Nawander. 

    The additional weight can be positive in the case of hospitalisation as overweight patients have fat reserves to help deal with the well-documented issue of poor food in medical facilities.  

    Nawander says that the obesity paradox is only apparent among older people who are mildly overweight and that in severely obese people, other mortality risk factors supersede its impact.  

    “Not that every overweight person benefits from the obesity paradox. Once a person’s BMI goes over 36 or 37 then the other ill-effects from being obese will determine the mortality outcome. There’s a small window where being overweight is good,” says Nawander.  

    According to Nawander, knowledge of the obesity paradox is filtering through to pricing life settlements contracts. Whereas the traditional approach would be to apply a certain amount of debits to a policy holder whose BMI was higher than the average for their cohort, now, firms are acting differently.  

    “If a person’s BMI was between 30 to 35, previously we would assume they had a lower life expectancy. But now we look at this differently and say that additional fat could be helpful from a life expectancy perspective,” he says.  

    Nawander is bullish that obesity’s risk to health can be tamed by the latest generation of medication, of which some has garnered much attention on social media from Tik Tok and Instagram influencers for their apparent weight-loss capabilities.   

    While these intravenous medications are designed for treating diabetes, their role in controlling the production of glucagon – a hormone produced by the pancreas to help regulate blood glucose levels – has produced positive results in relation to weight loss. 

    Nawander said that life settlement providers are now encountering applicants which don’t have diabetes but are using glucagon control medication to regulate their body weight.  

    “A future trend could emerge over the next 10 to 12 years where you start to see people who in general are close to their optimal weight.  Perhaps the current obesity epidemic will be contained to an extent,” he says. 

    Oliver says that the impact of the current generation of weight loss medication is limited because in theory they are only available to diabetes patients and a very specific subset of the overweight population.  

    But she points to the large rewards available to the pharmaceutical firm which manufactures the first mass-market obesity medication and says that currently there are 600 obesity treatments which are in phase three trials.  

    “There’s not a shortage of appetite amongst pharmaceutical companies to develop a successful medication. Phase three trials are at the advanced assessment stage and firms are usually pretty confident at this point, given the requirements of the first two phases which are rigorous and involve spending a substantial amount of money, that they will achieve success,” she says.  

    “There is a big pipeline of potentially important treatments coming onto the market, some are medications, others focus on lifestyle and possibly some surgical treatment,” Oliver adds.  

    Nawander is positive that an effective and low-cost obesity treatment would have multiple positive health implications for life expectancy.  

    “Mortality improvements won’t come from across the board as diseases will be affected differently by a reduction in obesity. I’m also not saying that someone who we are quoting to live 90 years today will live to 100 in five years’ time. But maybe it could shift from 90 to 93 over a relatively short period. It will be a step-by-step process,” he says. 

    2024 - March Longevity and Mortality Trends Volume 3 Issue 3 - March 2024
    Share. Twitter LinkedIn Email

    Related Posts

    Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024

    12 June 2025

    Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market

    12 June 2025

    Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets

    12 June 2025

    Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

    12 June 2025

    Comments are closed.

    Most Popular

    Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024

    12 June 2025

    Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market

    12 June 2025

    Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets

    12 June 2025

    Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

    12 June 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT